ArticleLupus science & medicine2025
Serum glutathione reductase level as a disease activity biomarker in systemic lupus erythematosus: a single-centre preliminary study.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Multi-Omics Landscape of Enzymatic Alterations in Systemic Lupus Erythematosus.Proteomics. Clinical applications · 2026Article
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
- Value of the Platelet-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Product in the Evaluation of Systemic Lupus Erythematosus Disease Activity.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate serum glutathione reductase (GR) levels in patients with SLE and to assess its association with disease activity.
methodsThe retrospective study collected clinical data, including serum GR, complement (C) 3 and C4 levels, among patients with SLE. The SLE Disease Activity Index 2000 (SLEDAI 2000) and SLE Disease Activity Score (SLE-DAS) were calculated, and C3 and C4 were used as controls to assess the importance of serum GR levels in evaluating SLE disease activity.
resultsSerum GR levels were significantly higher in patients with SLE (n=142) than in healthy controls (n=100). Serum GR levels were positively correlated with SLEDAI 2000 (ρ=0.335) and SLE-DAS (ρ=0.454) values in patients with SLE. Further, C3 and C4 were negatively correlated with SLEDAI 2000 (ρ = -0.544 and -0.418) and with SLE-DAS (ρ = -0.290 and -0.242). Fisher's Z test showed that GR was inferior to C3; however, similar to C4 in the correlation with SLEDAI 2000, whereas GR was comparable to C3 but superior to C4 in the correlation with SLE-DAS. The identification of moderate-to-severe disease activity based on SLEDAI 2000 of >6 revealed a receiver operating characteristic curve area under the curve (AUC) for GR of 0.700 (95% CI: 0.617 to 0.774), which was comparable to the AUC for C3 (0.784, 95% CI: 0.707 to 0.848) and C4 (0.697, 95% CI: 0.615 to 0.771); in determining moderate-to-severe disease activity as defined by SLE-DAS of >7.64, GR (0.767, 95% CI: 0.689 to 0.834) was equal to C3 (0.661, 95% CI: 0.576 to 0.738) but superior to C4 (0.617, 95% CI: 0.532 to 0.698).
conclusionSerum GR levels are positively correlated with SLE disease activity and exhibit clinical value in identifying moderate-to-severe disease activity in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.